BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7478604)

  • 1. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
    Lenny N; Meyers S; Hiebert SW
    Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
    Meyers S; Lenny N; Sun W; Hiebert SW
    Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.
    Erickson PF; Robinson M; Owens G; Drabkin HA
    Cancer Res; 1994 Apr; 54(7):1782-6. PubMed ID: 8137293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
    Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
    Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia.
    Sacchi N; Schiaffonati L; Magnani I; Pappalardo C; Hughes AJ; Darfler M; Hoogeveen AT
    Oncogene; 1996 Jan; 12(2):437-44. PubMed ID: 8570222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
    Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD
    Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inhibitory switch derepressed by pbx, hox, and Meis/Prep1 partners regulates DNA-binding by pbx1 and E2a-pbx1 and is dispensable for myeloid immortalization by E2a-pbx1.
    Calvo KR; Knoepfler P; McGrath S; Kamps MP
    Oncogene; 1999 Dec; 18(56):8033-43. PubMed ID: 10637514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.
    Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias.
    Wang J; Wang M; Liu JM
    Cancer Res; 1997 Jul; 57(14):2951-5. PubMed ID: 9230207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
    Nagata T; Werner MH
    J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains.
    Kim WY; Sieweke M; Ogawa E; Wee HJ; Englmeier U; Graf T; Ito Y
    EMBO J; 1999 Mar; 18(6):1609-20. PubMed ID: 10075931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
    Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
    Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
    Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C; Rowley JD; Nucifora G
    Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
    Licht JD
    Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
    [No Abstract]   [Full Text] [Related]  

  • 20. Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8).
    Odaka Y; Mally A; Elliott LT; Meyers S
    Oncogene; 2000 Jul; 19(32):3584-97. PubMed ID: 10951564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.